Online Experts Warn Of The Dangers of Developing Zantac Cancer
Until more is known for sure about the exact levels of NDMA in Zantac, former users will have to settle with a warning
Tuesday, July 14, 2020 - There was a time when the internet was new that people would not dare take the opinion of an online medical website. Over the years, reputable medical institutions have created online platforms that allow us to follow the developments in diseases and advise how to avoid them. Today's health crisis that is garnering the most online attention is Zantac Cancer. Scientists around the world are trying to get to the bottom of why the popular heartburn medicine and all other forms of ranitidine, have developed excess levels of NDMA, a known carcinogen. Tens of millions of heartburn and acid reflux sufferers have taken Zantac regularly and may have developed stomach, bladder, esophageal, or one of many other forms of the disease. The Food and Drug Administration (FDA) has confirmed without a doubt that such is the case. Since cancer has a latency time of up to a decade, millions of Americans could be walking around with a Zantac cancer time bomb ready to explode. Establishing the scientific facts around ranitidine cancer benefits everyone. Zantac cancer lawyers are helping families nationwide and offer a free no obligation consultation before filing a lawsuit case.
Experts and scientists at the influential website Drugs.com have weighed in with their thoughts regarding the current ranitidine crisis that has forced the FDA to recall all generic and brand name heartburn medication like Zantac. Zantac is the world's best-selling acid reflux medication with billions in annual sales. It is estimated that around 15 million heartburn sufferers reached for a Zantac tablet every year until 2020 when the drug was recalled. Unlike protein pump inhibitor drug Prilosec, Zantac is a histamine-2 blocker according to Drugs, and merely reduces the amount of acid the stomach produces. Both drugs stop the production of stomach acid that is necessary to fight off infection like the Coronavirus and those switching to Prilosec should be forewarned. Ranitidine is used to prevent stomach ulcers and gastroesophageal reflux disease (GERD) where stomach acid can back up causing heartburn, according to the article.
So little is known for sure about the health hazards of NDMA in Zantac that scientists can only give a warning. Harvard University Medical warn their readers, "If you or a family member take ranitidine (Zantac) to relieve heartburn, you may have heard that the FDA has found a probable human carcinogen (a substance that could cause cancer) in it." The New York Times warns that Zantac should not be sold and that users should throw out the Zantac tablets they have. WebMD warns: "A substance that could cause cancer has been found in some ranitidine heartburn and ulcer medicines, including the brand-name drug Zantac, and the source of this contamination is being investigated, the U.S. Food and Drug Administration says."
If you or a loved one have cancer of the stomach, bladder, or other cancer, and have taken Zantac regularly for years, you may qualify to file a claim against the drug manufacturer for having failed to warn you such a disease could develop.
More Recent Heartburn MedicineLawsuit News:
- Zantac Cancer Trials Are In Discovery To Begin In October 2022 | 7/19/2022
- Zantac Cancer Lawsuits Could Hinge On The Validity of Ranitidine Testing Methods | 7/11/2022
- Zantac Cancer Bellwether Trials In California Could Set The Stage For A Global Settlement Offer | 7/5/2022
- The FDA Recommended Protein Pump Inhibitor Drugs Like Prilosec And Nexium That May Damage Health More Than Zantac | 6/23/2022
- Truck Drivers, Firefighters, and Police Officers May Have Taken More Zantac Than People In Other Occupations | 6/20/2022
- Scientists Are Expected To Confirm That Ranidine Causes Gastrointestinal Cancer With Slam Dunk Testimony | 6/9/2022
- Scientific Hearings Will Start This September To Interview Zantac Cancer Expert Witnesses | 5/19/2022
- A Whistleblower Scientist Working For A Chinese Company Thinks NDMA Contamination Started In China | 5/12/2022
- Valisure's String Of Stunning Success Casts Doubt On The FDAs Ability To Police The Health Care Market | 5/2/2022
- Zantac Testing Accusations Heat Up With FDA Investigation Of Online Prescription Drug Testing Lab | 4/25/2022
- Study Finds Ranitidine Degrades Into 10,000 Nanograms of NDMA When Introduced To Simulated Stomach Conditions | 4/6/2022
- Potential Zantac Expert Witnesses Are Being Questioned By Zantac Defense Attorneys | 3/31/2022
- The FDA Requires That Drug Companies Regularly Test Ranitidine And Other Drug For NDMA | 3/24/2022
- Update: Where The Zantac Cancer Multidistrict Litigation (MDL) Stands Today | 3/12/2022
- Zantac Cancer Plaintiffs Look To The First Trial In October In Alameda California | 3/11/2022
- Zantac Cancer Plaintiffs Have Until June 30 To Finalize Their Claim | 3/7/2022
- Zantac Bellwether Trials May Focus On Ranitidine Testing Methods That Could Cause NDMA To Accelerate | 3/1/2022
- Valisure LLC's Motivations And Ranitidine Testing Methods May Not Be Scrutinized Before Trial | 2/24/2022
- Zantac Lawsuits May Go To Trial In California In October Of This Year | 2/18/2022
- Sanofi's History Of Reprehensible Corporate Behavior May Bolster Zantac Cancer Lawsuits | 2/10/2022
Lawyers for Zantac Heartburn Medicine Lawsuits
OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The Onder Law Firm has won more than $300 million in four talcum powder ovarian cancer lawsuits in St. Louis. Law firms throughout the nation often seek its experience and expertise on complex litigation.